NRC FORM 592M
(10-2020)

U.S. NUCLEAR REGULATORY COMMISSION

Materials Inspection Record

1. Licensee Name:	2. Docket Number(s):	3. License Number(s)
DLP Marquette General Hospital, LLC	030-18133	21-05432-04

4. Report Number(s):	5. Date(s) of Inspection:
2022-001	May 19, 2022

6. Inspector(s):	7. Program Code(s):	8. Priority:	9. Inspection Guidance Used:
Ryan Craffey	02240	2	IP 87131, IP 87132

10. Licensee Contact Name(s):	11. Licensee E-mail Address:	12. Licensee Telephone Number(s):
William Pyle, CNMT - RSO Jan Chudy, CNMT	N/A janice.chudy@mghs.org	906-228-9440 906-449-3180

13. Inspection Type:	14. Locations Inspected:	15. Next Inspection Date (MM/DD/YYYY):
☐ Initial ☑ Routine ☐ Announced ☐ Non-Routine ☑ Unannounced	☑ Main Office ☐ Field Office ☐ Temporary Job Site ☐ Remote	05/19/2024 ☑ Normal ☐ Extended ☐ Reduced ☐ No change

16. Scope and Observations:

DLP Marquette General Hospital d/b/a UP Health System - Marquette is a 222-bed specialty care hospital and level II trauma center authorized to use byproduct material for diagnostic and therapeutic medical purposes at its facility in Marquette, Michigan. At the time of the inspection, six full-time nuclear medicine technologists performed diagnostic administrations of radiopharmaceuticals using unit and bulk doses at one of three departments - general nuclear medicine, cardiology, and a stationary PET imaging trailer which operated Tuesdays, Wednesdays and Thursdays. Since moving to the new hospital on Baraga Avenue in summer 2019, the licensee no longer received generators, and instead received only unit and bulk doses of Tc-99m from a local radiopharmacy, as well as unit doses of positron emitting radionuclides (F-18 and Cu-64) by air from a cyclotron radiopharmacy in suburban Detroit. The licensee also performed occasional I-131 and Ra-223 therapies, and had performed one Y-90 microspheres therapy since the last inspection. The licensee maintained an RSC, which met quarterly, and retained the services of a medical physics consultant to perform quarterly audits of the program.

The inspector toured all three departments at the hospital in Marquette. All areas were adequately posted, and all licensed material was adequately secured. Independent and confirmatory surveys in the department found no residual contamination or exposures to members of the public in excess of regulatory limits. The facility matched the description provided by the licensee in its request to add the location dated June 18, 2018. The inspector observed the administration of diagnostic radiopharmaceuticals at each department as well as the receipt of packages containing licensed material, and noted the use of adequate ALARA practices throughout. All technologists were knowledgeable of radiation protection principles, regulatory requirements, and licensee procedures, and wore assigned personnel dosimetry.

The inspector reviewed a selection of the licensee's records, including RSC meeting minutes, consultant audits (including instrument quality control records and sealed source inventory and leak test documentation), written directives and treatment documentation for I-131, Ra-223, and Y-90 microsphere therapies, a variety of routine nuclear medicine records, and personnel dosimetry reports which documented occupational exposures that were consistent with licensed activities and below regulatory limits.

No violations of NRC requirements were identified as a result of this inspection.